Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanotech Researchers Say Federal Agenda “Like A Ship Without A Captain”

This article was originally published in The Tan Sheet

Executive Summary

The National Science and Technology Council's prioritization of nanotechnology research needs is raising questions about the federal government's ability to devise an effective strategy for addressing the potential risks of materials increasingly found in consumer products on the near-atomic scale

You may also be interested in...



U.S. Nanotech Research Spending Drips As Market Growth Pours – PEN

The U.S. is spending about half as much as Europe on nanotechnology risk research even as three to four consumer products with nano-engineered materials reach the market every week, according to the Project on Emerging Nanotechnologies

U.S. Nanotech Research Spending Drips As Market Growth Pours – PEN

The U.S. is spending about half as much as Europe on nanotechnology risk research even as three to four consumer products with nano-engineered materials reach the market every week, according to the Project on Emerging Nanotechnologies

U.S. Nanotech Research Spending Drips As Market Growth Pours – PEN

The U.S. is spending about half as much as Europe on nanotechnology risk research even as three to four consumer products with nano-engineered materials reach the market every week, according to the Project on Emerging Nanotechnologies

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS101025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel